| General |
Implemented histology/behavior reportability changes for 2022+
- Updated edits to not allow cases with histology/behavior codes 8211/2, 8261/2, 8263/2, 8483/2, 8484/2, 8590/1, 9200/1, 9261/1 and diagnosis year 2022 or later
- Updated NCDB and RCRS submissions to not include cases with histology/behavior code 8210/2 and diagnosis year 2022 or later
|
| Data Exchange |
Suppressed RCRS/NCDB Edit N2867 (LN Status Femoral-Inguinal, Para-Aortic, Pelvic, Schema ID, Required) as this SSDI has been split out into three new fields in 2022. |
| General |
Updated Plasma Cell Myeloma SSDIs to 5 if cases not eligible for R-ISS staging. |
| Data Entry |
Open 2022+ Covid Reporting to All Facilities |
| Data Entry |
Update Macroscopic Evaluation of the Mesorectum to only display in Case Data View when Topography is "C20.9" |
| Data Entry |
Add RISS stage groups to AJCC Clinical Stage Group drop downs for 2022+ multiple myeloma cases (AJCC ID 82.1). RISS Stage Group is required for eligible plasma cell myeloma types starting in 2022. |
| Reports |
Fixed a bug in ACoS Follow Up report and Follow Up Control List report that set the end date at the beginning of the end year rather than the end |